How big is the Middle East And Africa Glucagon-like Peptide-1 Agonists Market?

The Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 124.32 million in 2024 and grow at a CAGR of 7.26% to reach USD 175.28 million by 2029. Read More

What is the current Middle East And Africa Glucagon-like Peptide-1 Agonists Market size?

In 2024, the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 124.32 million. Read More

Who are the key players in Middle East And Africa Glucagon-like Peptide-1 Agonists Market?

AstraZeneca, Sanofi, Eli Lilly and Company, Novo Nordisk A/S and Pfizer Inc. are the major companies operating in the Middle East And Africa Glucagon-like Peptide-1 Agonists Market. Read More

What years does this Middle East And Africa Glucagon-like Peptide-1 Agonists Market cover, and what was the market size in 2023?

In 2023, the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size was estimated at USD 115.29 million. The report covers the Middle East And Africa Glucagon-like Peptide-1 Agonists Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Share

Statistics for the 2023 & 2024 Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists market share, created by Mordor Intelligence™ Industry Reports. Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Industry

The Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, holding their presence in all regions.